Salute e Benessere

Endo Announces New Peyronie's Disease Data Presented at the American Urological…

The three new Endo-supported research presentations are below: The three new Endo-supported research presentations are below: About Peyronie's DiseasePeyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be painful during arousal and intimacy. 1It is estimated that PD can affect as many as 1 in 10 men in the U.S., 2but diagnosis rates remain low because men with PD may be too uncomfortable to...
PR Newswire
07/05/2024

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent…

~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and...
Nasdaq GlobeNewswire
07/05/2024

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance…

Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investorsProceeds to support ongoing mid- to late-stage clinical development programs for Company's lead I&I product candidate, obexelimabWALTHAM, Mass., May07, 2024(GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and...
Nasdaq GlobeNewswire
07/05/2024

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and…

- Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the study Monitoring Committee- -Presented preclinical data demonstrating the potential synergy between VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft at the ASGCT Annual Meeting; emphasizes VCN-01's potential in diverse chemotherapy combinations for improved efficacy in...
Nasdaq GlobeNewswire
07/05/2024

Healthier Habits Drive Salad Container Market to Top US$ 3,119.7 Million by 2034…

As per industry experts, the market valuation is expected to surpass US$ 3,119.7 million by 2034. With last-mile delivery services making a comeback, the industry is expected to report a CAGR of 3.7% through 2034. As of 2024, the market is valued at US$ 2,169.3 million. As per industry experts, the market valuation is expected to surpass US$ 3,119.7 million by 2034. With last-mile delivery services making a comeback, the industry is expected to report a CAGR of3.7%through 2034...
PR Newswire
07/05/2024

/C O R R E C T I O N -- The Adecco Group/

ZURICH, May 7, 2024 /PRNewswire/ -- ZURICH ,May 7, 2024/PRNewswire/ -- Denis Machuel, Adecco Group CEO, commented: "The Group demonstrated strong operational progress in the first quarter. We achieved revenue stability and maintained firm pricing discipline amidst challenging market conditions while driving further cost improvement across the business. Adecco delivered significant market share gains with a healthy gross margin. Akkodis faced ongoing tech staffing...
PR Newswire
07/05/2024

A4P HAS ACHIEVED THE KING'S AWARD FOR ENTERPRISE IN INTERNATIONAL TRADE

A4P is a scientific consultancy specializing in bioanalytical and biosample project management, biomarker strategy and logistics solutions in support of clinical research around the world. A4P recently joined LabConnect forming a combined international team which brings an unparalleled breadth and depth of technical and scientific expertise to help clients successfully achieve pre-clinical and clinical trial objectives sooner. A4P is a scientific consultancy specializing in bioanalytical and...
PR Newswire
07/05/2024

neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA…

Tariq is a seasoned healthcare specialist, bringing with him a wealth of experience in healthcare start-up ventures and strategic C-level leadership roles. Throughout his career, Tariq has worked in various private and publicly listed multinationals, semi-government organizations, and start-up companies across the UK, Europe, and the Middle East. Tariq is a seasoned healthcare specialist, bringing with him a wealth of experience in healthcare start-up ventures and strategic C-level leadership…
PR Newswire
07/05/2024

Coloplast Finance B.V. - Interim Financial Report, H1 2023/24

H1 2023/24 Interim financial results, H1 2023/241 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin 1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies.Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional...
Nasdaq GlobeNewswire
07/05/2024

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced…

The study, known as BRAVO (Bladder Cancer Recurrence Analysis in Veterans and Outcomes), is a retrospective, propensity score matched analysis that evaluated oncologic outcomes following BLC compared to WLC alone in patients from the Veterans Affairs Healthcare System. The study addresses a lack of practical real-world data comparing the impact of BLC versus WLC, specifically for recurrence, progression, and survival. The results of this study confirm that BLC use is associated with positive and…
PR Newswire
07/05/2024

2024 World Brain Day Dedicated to Brain Health and Prevention

While there are no definitive cures for many neurological disorders, understanding and addressing risk factors can significantly alleviate this burden. A 2021 Global Burden of Disease Study revealed that over 3.40 billion individuals suffered declines in nervous system health, resulting in 11.1 million deaths attributed to related conditions. While there are no definitive cures for many neurological disorders, understanding and addressing risk factors can significantly alleviate this burden...
PR Newswire
07/05/2024

Novo Nordisk Foundation announces an international open call for research…

The Summit focuses on the interplay between non-communicable diseases, infectious diseases, and climate change as well as novel breakthrough-enabling technologies. The Summit brings together leading scientists, philanthropists and policymakers, with the overarching purpose of paving the way for new scientific breakthroughs that address these pressing issues. The Summit focuses on the interplay between non-communicable diseases, infectious diseases, and climate change as well as novel...
PR Newswire
07/05/2024

Groupe Casino: FRH and Casino request exemption/extension under Dutch Financial…

FRH and Casino request exemption/extension under Dutch Financial Supervision Act Paris, 7 May 2024Casino Guichard-Perrachon S.A. (“Casino”; Euronext Paris: CO; ISIN: FR0000125585) hereby informs as follows: also on behalf of France Retail Holdings S.à r.l. (an entity ultimately controlled by Mr. Daniel Křetínský) (“FRH”), it is hereby announced that FRH and Casino have today jointly submitted a petition to the Enterprise Chamber of the Amsterdam Court of Appeal, the Netherlands,...
Nasdaq GlobeNewswire
07/05/2024

CMR Surgical appoints Shlomi Cohen as Chief Financial Officer

CMR Surgical appoints Shlomi Cohen as Chief Financial OfficerShlomi Cohen is a medical devices expert with significant financial and operational experience.CAMBRIDGE, UK – 7 May 2024, 07:00 (BST). CMR Surgical (CMR or 'the Company') – the global surgical robotics business today announces the appointment of Shlomi Cohen as Chief Financial Officer (CFO), effective immediately.Shlomi Cohen is a senior financial and operations executive with extensive global leadership...
Nasdaq GlobeNewswire
07/05/2024

Memo Therapeutics increases Series C financing to CHF 45 million

PRESS RELEASE Memo Therapeutics increases Series C financing to CHF 45 millionAdditional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investorsProceeds will be used to expand Phase II of best-in-class anti-BK Virus antibody to become the largest study ever conducted for BK virus infection in kidney transplantation Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG(or “MTx”), a late-stage...
Nasdaq GlobeNewswire
07/05/2024

Orion Corporation: Change in Orion Group Executive Management Board as of 31 May…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS 7 May 2024 at 08.30 EEST Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025 Olli Huotari, Senior Vice President responsible for Corporate Functions organization (including, i.a., Communications, Compliance, Corporate Responsibility, Intellectual Property Rights, Legal Affairs and Public Affairs) of the Orion Group and Secretary to the Board of Directors of...
Nasdaq GlobeNewswire
07/05/2024

Coloplast strengthens ostomy care portfolio with three significant product…

The company has received reimbursement approval in the UK for Heylo™, the world's first digital leakage notification system, and expands its SenSura® Mio ostomy range with two new products. As part of our 2025 strategy, Strive25, we set an ambition to significantly raise the standard of care for our users and bring new products to market at a higher pace. I am excited to see that our Innovation unit continues to deliver on this commitment, latest with these three new products in Ostomy Care,...
Nasdaq GlobeNewswire
07/05/2024

Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24

H1 2023/24 Interim financial results, H1 2023/241 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin 1)of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies.Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional...
Nasdaq GlobeNewswire
07/05/2024

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate…

Valneva Reports First Quarter 2024 Financial Results andProvides Corporate UpdatesQ1 financial highlightsTotal revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipated full year guidanceCash position of €176.6 million, including €95 million from sale of Priority Review Voucher (PRV) 1.Significantly extended cash runway with recent update of debt financing agreement 2 Substantially lower cash burn expected in 2024 as Valneva expects to...
Nasdaq GlobeNewswire
07/05/2024

Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General…

Ultimovacs remains committed to continuing the clinical development strategy and exploring multiple pathways for UV1. The negative INITIUM results have had important consequences for the Company. Implemented cash preservation initiatives extends the anticipated financial runway to the fourth quarter of 2025, beyond the anticipated topline readout of the FOCUS and DOVACC trials. The UV1 vaccine was granted Fast Track designation from the U.S. Food and Drug Administration (FDA) and Orphan...
Nasdaq GlobeNewswire
07/05/2024

Sandoz reports first quarter 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEStrong first quarter performance, with net sales[1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)Biosimilar business growing 21% in constant currencies All regions contributing to growthAcquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024Basel, May 7, 2024 –Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced...
Nasdaq GlobeNewswire
07/05/2024

AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange

Denis Machuel, Adecco Group CEO, commented: Denis Machuel, Adecco Group CEO, commented: "The Group demonstrated strong operational progress in the first quarter. We achieved revenue stability and maintained firm pricing discipline amidst challenging market conditions while driving further cost improvement across the business. Adecco delivered significant market share gains with a healthy gross margin. Akkodis faced ongoing tech staffing headwinds while achieving solid growth in its...
PR Newswire
07/05/2024

The 26th China (Guangzhou) International Building Decoration Fair Scheduled for…

The 2024 CBD (Guangzhou) is set to further its legacy with an expanded exhibition space of 420,000 square meters and an estimated 2,200 participating companies. The event will feature an optimized and upgraded "5+1" layout, encompassing five thematic areas and the second Guangzhou International Sanitary and Bath Ware Fair, which is set to take place concurrently with the 2024 CBD (Guangzhou) in Area A of the Canton Fair Complex. The approach highlights the CBD (Guangzhou)'s…
PR Newswire
07/05/2024

Biogénesis Bagó and ACSAD working together to improve livestock productivity in…

The agreement was signed by Dr. Nasr Al-Din Obaid, Director General of ACSAD and the CEO of Biogenesis Bagé, Mr. Esteban Turic. During the event the Ministers of Agriculture of Jordan, Mr. Khaled Hanifat, and Lebanon, Mr. Abbas Al-Haj Hassan, as well as Daniel Helou, Biogénesis Bagó's Regional Director for MENA and Central Asia were also present. This agreement is key in promoting joint efforts that allow the region's authorities to make available scientific and quality solutions to improve the…
PR Newswire
06/05/2024
Altri  Comunicati